Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics Deal validates Jeito’s unique investment model of selecting high–quality assets developed by world-leading teams in therapeutic areas with high unmet need Paris, France, November 29th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to […]

Continue Reading